MiMedx Group
-
Biologics
MiMedx Announces Executive to Lead its International Operations and Provides Update on Company’s International Progress
MARIETTA, Ga., June 7, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Hospitals
AmnioFix® Injectable Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for the Treatment of Osteoarthritis of the Knee
MARIETTA, Ga., March 9, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Biologics
MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts To Regulate Diabetic Stem Cells
MARIETTA, Ga., Aug. 26, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Financial
Company Shares of MiMedx Group, Inc Drops by -13.05%
By Brian Bickford MiMedx Group, Inc (NASDAQ:MDXG) has lost 13.05% during the past week and dropped 1.29% in the last…
Read More » -
Financial
MiMedx Group Lifted to Strong-Buy at Zacks (MDXG)
By Robert Jamerson Zacks upgraded shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a strong-buy rating in a report issued on…
Read More » -
Financial
MiMedx Reports Record First Quarter 2015 Revenue of $40.8 Million
MARIETTA, Ga., April 13, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More »